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Background and aims: Familial hypercholesterolaemia (FH) is an autosomal-dominant disease with fre-
quency of 1/500 to 1/250 that leads to premature coronary heart disease. New approaches to identify FH
mutation-carriers early are needed to prevent premature cardiac deaths. In a cross-sectional study of the
Avon Longitudinal Study of Parents and Children (ALSPAC), we evaluated the biochemical thresholds for
FH screening in childhood, and modelled a two-stage biochemical and sequencing screening strategy for
FH detection.
Methods: From 5083 ALSPAC children with cholesterol measurement at age nine years, FH genetic
diagnosis was performed in 1512 individuals, using whole-genome or targeted sequencing of known FH-
causing genes. Detection rate (DR) and false-positive rate (FPR) for proposed screening thresholds (total-
cholesterol > 1.53, or LDL-C > 1.84 multiples of the median (MoM)) were assessed.
Results: Six of 1512 sequenced individuals had an FH-causing mutation of whom ﬁve had LDL-C > 1.84
MoM, giving a veriﬁcation-bias corrected DR of 62.5% (95% CI: 25e92), with a FPR of 0.2% (95% CI: 0.1
e0.4). The DR for the TC cut-point of 1.53 MoMwas 25% (95% CI: 3.2e65.1) with a FPR of 0.4% (95% CI: 0.2
e0.6). We estimated 13 of an expected 20 FH mutation carriers (and 13 of the 20 parental carriers) could
be detected for every 10,000 children screened, with false-positives reliably excluded by addition of a
next generation sequencing step in biochemical screen-positive samples.
Conclusions: Proposed cholesterol thresholds for childhood FH screening were less accurate than pre-
viously estimated. A sequential strategy of biochemical screening followed by targeted sequencing of FH
genes in screen-positive children may help mitigate the higher than previously estimated FPR and reduce
wasted screening of unaffected parents.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Familial hypercholesterolaemia (FH) is an inherited disorderrani).
r Ireland Ltd. This is an open acceswith prevalence estimated from recent epidemiological[1] and
sequencing studies[2,3] of 1 in 250, higher than historical estimates
of 1 in 500. Autosomal dominant FH is caused by mutations in
genes encoding the low-density lipoprotein receptor (LDLR) [4],
apolipoprotein B (APOB) [5], and proprotein convertase subtilisin/
kexin type 9 (PCSK9) [6]. Autosomal recessive FH is caused by
mutations in the LDLRAP1 gene[7]. Characteristics include elevated
total cholesterol (TC) and LDL-C, cutaneous lipid deposition, and as article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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patients exhibit a 13-fold excess risk of CHD compared to the
general population[1], with FH men typically developing CHD in
their 50s, and women in their 60s[8]. European guidelines
recommend early high potency statin treatment to achieve
maximal LDL-C reduction[9].
Pre-clinical screening of ﬁrst-degree relatives of a patient
(cascade testing) has been carried out effectively in Europe[10,11].
However, index cases are usually ascertained opportunistically (at
clinical presentation) rather than systematically. Worldwide, fewer
than 5% of FH individuals have a diagnosis, with only 12% known
and treated in the UK [9].
New approaches are needed to identify affected individuals
before they develop CHD. In 2007,Wald et al. proposed biochemical
FH screening bymeasurement of TC and LDL-C in childhood (one to
nine years of age), when the separation of the lipid distribution in
affected and unaffected is greater than later in life[12]. The detec-
tion rate (DR), estimated for an LDL-C cut-point of 1.84 multiples of
the median (MoM), or a TC of 1.53 MoM was 85% or 88% respec-
tively, for a false positive rate (FPR) of 0.1%. It was estimated the
affected parent could then be detected as the one with the higher
cholesterol, with an FPR of 4%. A preliminary report based on ~200
children screened at the age of 15 months was published in 2011
[13], and the outcome of a 10,000 child screening study was re-
ported in 2016[14].
However, in the primary report[12], the proposed biochemical
thresholds were based on historic case-control data: lipid values in
FH cases were ascertained from hospital clinic records, while those
in controls were from unaffected siblings of patients, whomay have
been from a different age stratum to the cases, or from values in
healthy population surveys from the same geographical region,
conducted within 5 years of the case ascertainment. In addition, FH
was conﬁrmed either by clinical criteria or by mutation-detction
methods that predated the more sensitive next generation DNA
sequencing (NGS).
In the outcome study[14], a more relaxed case deﬁnition was
adopted than in the prior meta-analysis of case-control data. A case
was deﬁned as either carriage of an FH mutation or a persistently
high cholesterol, which risks mixing polygenic hyper-
cholesterolaemia with monogenic FH. Using cholesterol both in the
test and case deﬁnition also complicates assessment of screening
performance. Finally, a 48 variant mutation detection panel was
used rather than a sequencing approach, which runs the risk of
missing cases with FH mutations not represented in the panel.
We, therefore, evaluated the performance of previously pro-
posed LDL-C and TC thresholds for the detection of FH in a general
population sample of children from the Avon Longitudinal Study of
Parents and Children (ALSPAC) [15], using NGS of FH genes as the
diagnostic standard.2. Materials and methods
ALSPAC study description and the ethical approval are presented
in the Supplementary Material.2.1. Cholesterol measurement
At a mean (standard deviation, SD) age of 9.9 years (4 months),
TC, LDL-C (calculated using the Friedewald equation) and other
lipids and apolipoproteins were measured in non-fasting blood
samples from 5083 ALSPAC children, using methods described
previously[16]. Non-high-density-lipoprotein cholesterol (non-
HDL-C) was calculated by subtracting HDL-C from TC.2.2. DNA sequencing for FH-causing mutations
A 30% random sample of ALSPAC participants (N ¼ 1503) were
previously selected and 1497 (29.5%) successfully completed low-
read depth whole genome sequencing (WGS, see Supplementary
Material), as part of the UK10K project[3].
In addition, we conducted targeted high-read depth sequencing
(see Supplementary Material) of the known FH genes (LDLR, APOB,
PCSK9, and LDLRAP1) in 55 samples selected by stratiﬁed random
sampling from each quartile of the LDL-C distribution, restricting to
those that were also included in the UK10K project. A further 15
samples with an LDL-C>1.84 MoM, who also had a TC > 1.53 MoM,
were selected for targeted NGS, giving a total of 70 with targeted
sequencing data (Fig. 1), and 1512 samples with any sequencing
data. No other clinical characteristics were included in the selection
of these individuals. The variant interpretation methods are shown
in the Supplementary Material.
2.3. Genotyping of common LDL-C-raising alleles
Since carriage of a high burden of common LDL-C-raising alleles
can mimic the biochemical features of monogenic FH[17,18], and
might contribute to a false positive FH diagnosis, we also obtained
genotypes for six LDL-C-associated SNPs: rs629301 (CELSR2),
rs1367117 (APOB), rs6544713 (ABCG8), rs6511720 (LDLR), rs429358
(APOE), rs7412 (APOE), in the whole cohort. The methods used for
genotyping, generating and validating a weighted LDL-C genetic
risk score were described previously[17,18].
2.4. Statistical analysis
Data were analysed using R (http://www.r-project.org) and
WINPEPI[19]. We compared categorical and continuous variables
using c2 and two sample t-tests respectively, generating p-values
on the basis of the null hypothesis of no difference between the
groups. To evaluate the performance of previously proposed LDL-C
(1.84 MoM, 1.66 MoM and 1.58 MoM) and TC cut-offs (1.53 MoM,
1.42 MoM and 1.37 MoM) [12], we obtained estimates of DR, FPR,
predictive value of a positive test (PPV), predictive value of a
negative test (NPV), and odds of being affected given a positive test
[20]. Since all samples with LDL-C >1.84 MoM or TC > 1.53 MoM
underwent targeted sequencing but only a proportion of samples
with LDL-C or TC below these values was sequenced, the study
design was subject to veriﬁcation bias. Information on the number
of participants with FH mutations in the sampled group with LDL-
C/TC below the pre-speciﬁed cut-points was therefore used to es-
timate the prevalence of FH mutations in the whole cohort by
scaling. 95% conﬁdence intervals were based on binomial
probabilities.
The performance of the child-parent screening approach was
evaluated with and without adjustment for veriﬁcation bias and
compared with previous estimates[12,14]. We also estimated the
effect of misclassiﬁcation of case status arising from imperfect ac-
curacy of NGS screening performance, based on a 90% rather than
100% sensitivity of NGS, following the method of Greenland
et al.[21]. The FPR of NGSwas assumed to be equal to 0%, because all
samples with mutations identiﬁed by NGS undergo conﬁrmation
by Sanger sequencing.
3. Results
Mean (SD) and median (interquartile range) values of LDL-C, TC,
and a range of other variables were similar between the 1512
children who successfully underwent whole genome, targeted
sequencing, or both, and the 3571 who did not (Supplementary
Fig. 1. Study design.
Of 5083 ALSPAC samples with lipids measured at the age of nine years, 1497 were successfully sequenced as part of the UK10K project. 55 of these, selected by stratiﬁed random
sampling from each LDL-C quartile, underwent targeted sequencing (LDLR, APOB, PCSK9, LDLRAP1) together with 15 samples from children with LDL-C>1.84 MoM or TC > 1.53 MoM.
Six FH-causing mutations were identiﬁed. Six samples failed NGS sequencing.
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All regions of the known FH genes were sequenced at an average
of 7  read depth in the UK10K WGS sub-sample[3] and, with the
exception of exon 2 in APOB, at aminimumof 15 read depth in the
targeted sequencing sub-sample (Supplementary Fig. 1). The
overall coverage of LDLRAP1was insufﬁcient (Supplementary Fig. 1)
therefore analysis of variants in this gene, associated with the rare
recessive FH, was excluded. An FH-causing mutationwas identiﬁed
in six individuals (Table 1). Four of the identiﬁed mutations located
in LDLR had previously been reported as being FH-causing[22,23],
and were predicted to be ‘damaging’ using in silico programmes.
Two children carried the most common FH mutation,
p(Arg3527Gln), located in APOB. Compared to the children who
underwent sequencing but inwhom no FHmutationwas identiﬁed
(n ¼ 1506), FH mutation carriers had a higher LDL-C (mean (SD):
4.72 (1.35) mmol/L vs. 2.34 (3.14) mmol/L, p ¼ 0.02), TC (6.34 (1.32)
mmol/L vs. 4.27 (0.72) mmol/L, p ¼ 0.03), and apolipoprotein B
(104.3 (30) mg/dL vs. 58.5 [13]mg/dL, p ¼ 0.03) (p ¼ 0.02)
(Supplementary Table 3).
Median LDL-C in the whole sample was 2.3 mmol/L, yielding FH
diagnostic cut-points of 4.25 mmol/L (1.84 MoM for an estimated
FPR of 0.1%), 3.84 mmol/L (1.66 MoM for an estimated FPR 0.5%),
and 3.65 mmol/L (1.58 MoM for an estimated FPR 1%) (Fig. 2).
Median TC was 4.23 mmol/L yielding TC cut-points of 6.47 mmol/L
(1.53 MoM; for an estimated FPR of 0.1%), 6.01 mmol/L (1.42 MoM;
estimated FPR 0.5%), and 5.80 mmol/L (1.37 MoM; estimated FPR
1%).
For all three LDL-C cut-points, based on the sequenced sample
alone, the observed DR was 83% (95% CI: 36e100), lower than theestimated DRs of 85%, 93%, and 96%, respectively, from historic data
[12]. The corresponding FPRs were also higher at 0.8% (95% CI:
0.4e1.4), 1.53% (95% CI:1.08e2.44), and 2.3% (95% CI: 1.6e3.2),
respectively (Table 2A; Supplementary Table 4A). FH screening
using TC was less accurate than LDL-C, shown in Table 2B, and
Supplementary Table 4B.
The study design introduced the potential for veriﬁcation bias
because we exhaustively sequenced individuals with LDL-C>1.84
MoM, but only a stratiﬁed random sample of individuals with LDL-C
below this threshold. Among the 1495 sequenced participants with
LDL-C<1.84 MoM, we identiﬁed one with an FH mutation. We
therefore re-estimated the childhood LDL-C screening performance
on the assumption that among all 5066 individuals with LDL-
C<1.84 MoM either there would be no further FH mutations or,
under the more conservative assumption, that there would be a
total of 5066/1495 (~3) individuals with a mutation (see
Supplementary Table 6 for calculations). The corresponding esti-
mates of the screening performance adjusted for veriﬁcation bias
are shown in Table 2 column III. The DR for an LDL-C of 1.84 MoM,
on the assumption of no further false negatives was 83% (95%
CI:35.9e99.6), with an FPR improvement to 0.2% (95% CI: 0.1e0.4).
However, after adjustment for veriﬁcation bias, the DR fell to 62.5%
(95%CI: 24.5e91.5) with an FPR of 0.2% (95% CI: 0.1e0.4). Further
scenarios were modelled where the sequence DR for FH-causing
mutations was either 100% or 90%, the latter being an extremely
conservative lower boundary based on the performance of different
NGS methods[3,24,25]. The effect of imperfect accuracy of NGS on
screening performance is shown in Table 2, column IV.
The TC threshold of 1.53 MoM had a lower DR of 33% (95%CI:
Table 1
FH mutations identiﬁed in the study.
Gene DNA:Protein change LDL-C of the carrier (mmol/L) (percentile) TC of the carrier (mmol/L) (percentile) Mutation Predictions
PolyPhen-2 SIFT Mutation Taster
FH mutations
LDLR c.680_681delAC:p.(Asp227Glyfs*12) 6.48(99th) 7.83(99th) Frame shift mutation
c.722T > C:p.(Phe241Ser) 4.47(99th) 5.63(97th) PD NT DC
c.940G > A:p.(Gly314Arg) 2.79(80th) 4.61(72nd) Likely to affect splicing
c.1897C > T:p.(Arg633Cys) 5.36(99th) 7.46(99th) PD NT DC
APOB c.10580G > A:p.(Arg3527Gln) 4.27(99th) 6.38(99th) PD NT DC
4.52(99th) 6.17(99th) PD NT DC
Full characteristics of the variant carriers are shown in Supplementary Table 2.
PD ¼ probably damaging; PsD ¼ possibly damaging; NT ¼ not tolerated; T ¼ tolerated; DC ¼ disease causing; P ¼ polymorphism.
Fig. 2. LDL-C distribution at 9 years of age in sequenced children.
Red dashed lines indicate FH diagnostic LDL-C cut-points (1.84 MoM, 1.66 MoM, and 1.58 MoM). Five of six mutation carriers (marked red) had LDL-C above the cut-points. Two
children carried a loss-of-function variant (p.Arg46Leu) in the PCSK9 gene, known to lower LDL-C (marked green) [6,26]. One child was found to have a rare PCSK9 variant
(p.His553Arg) associated with increased LDL-C (marked orange) [27]. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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veriﬁcation bias. DR improved with lower cut-points at the expense
of a higher FPR (Supplementary Table 4B). Detection rate of FH
mutation carriers using non-HDL-C cut-offs was very similar to the
DR produced by TC cut-offs, with slightly lower FPR
(Supplementary Table 3C).
The mean (SD) predicted LDL-C weighted gene score based on
six SNPs was 0.62 (0.23) mmol/L (Supplementary Fig. 2), which did
not differ from the previously studied Whitehall II sample (mean
0.63 (0.22) mmol/L), where a 1 SD increase in the score was asso-
ciated with a 0.33 (SE ¼ 0.02) mmol/L increment in LDL-C(17). In-
dividuals with LDL-C>1.84 MoM but with no FH mutation had a
higher predicted LDL-C gene score (0.72(0.17) mmol/L) than those
with LDL-C<1.84 MoM (0.63 (0.23) mmol/L, p ¼ 0.09). The meanscore in those who were found to be FH mutation positive was
lower than in those with an LDL-C>1.84MoM but with nomutation
identiﬁed (0.59 (0.21) mmol/L vs. 0.72 (0.17) mmol/L, p ¼ 0.23,
consistent with previous ﬁndings(17, 18)). All but one (91.7%) of
those with LDL-C>1.84 MoM and no FH mutation detected had
predicted LDL-C weighted gene score above the bottom quartile, of
whom 42% had score in the top quartile, which suggests polygenic
hypercholesterolaemia as an alternative diagnosis in these
individuals.
Information on FH mutations and LDL-C in the parents of the
children studied was unavailable. However, we estimated the
likely accuracy of the child-parent screening based on the
observed performance of 1.84MoM LDL-C cut-point in ALSPAC
and compared it with the original report by Wald and colleagues.
Table 2
Assessment of the biochemical screening for FH based on: (A) LDL-C, (B) TC, at nine years of age.
A.
LDL-C I II III IV
1·84 MoM (4.25 mmol/L) Wald et al. 2007
DR (95%CI) 83% (35.9 to 99.6) 83% (35.9 to 99.6) 62.5% (24.5 to 91.5) 66.7% (29.9 to 92.5) 85% (79 to 89)
FPR (95%CI) 0.8% (0.4 to 1.4) 0.2% (0.1 to 0.4) 0.2% (0.1 to 0.4) 0.2% (0.1 to 0.4) 0.1%
PPV (95%CI) 29.4% (10.3 to 56.0) 29.4% (10.3 to 56.0) 29.4% (10.3 to 56.0) 35.3% (14.2 to 61.7) NA
NPV (95%CI) 99.9% (99.6 to 100) 99.9% (99.9 to 100) 99.9% (99.6 to 99.9) 99.9% (99.8 to 100)
OAPR (95%CI) 5:12 (0.15 to 0.72) 5:12 (0.15 to 0.72) 5:12 (0.15 to 0.72) 6:11 (0.23 to 0.83)
B.
TC I II III IV
1·53 MoM (6.47 mmol/L) Wald et al. 2007
DR (95%CI) 33% (4.3 to 77.7) 33% (4.3 to 77.7) 25% (3.2 to 65.1) 22.2% (2.8 to 60.0) 88% (84 to 92)
FPR (95%CI) 0.9% (0.5 to 1.6) 0.3% (0.15 to 0.5) 0.4% (0.2 to 0.6) 0.4% (0.2 to 0.6) 0.1%
PPV (95%CI) 12.5% (1.6 to 38.3) 12.5% (1.6 to 38.3) 9.1% (1.1 to 29.2) 9.1% (1.1 to 29.2) NA
NPV (95%CI) 99.7% (99.3 to 99.9) 99.9% (99.8 to 100) 99.9% (99.7 to 100) 99.9% (99.7 to 99.9)
OAPR (95%CI) 2:14 (0.02 to 0.43) 2:14 (0.02 to 0.43) 2:20 (0.01 to 0.32) 2:20 (0.01 to 0.32)
The data analysis were based on: I, sequenced participants only; II, extrapolation to the whole cohort (n¼ 5083), assuming that there were no further FHmutations present in
the not-sequenced participants; III, correction for veriﬁcation bias; IV, correction for veriﬁcation bias and misclassiﬁcation based on a reduced sensitivity of NGS (90%). All
values are shown in Supplementary Table 5 and Supplementary Table 6.
MoM ¼ multiple of the median. DR ¼ detection rate. CI ¼ conﬁdence intervals. FPR ¼ false positive rate. PPV ¼ positive predictive value. NPV ¼ negative predictive value.
OAPR ¼ odds of being affected given a positive test. NA ¼ not available.
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in which the prevalence of FH is 1 in 500, and using the Wald
et al. estimates for the DR and the FPR for biochemical screening
of 85% and 0.1%, respectively, we would expect to ﬁnd 17 true
positives (TP) and 10 false positives (FP), giving an estimated PPV
of 63%. Using the assumption of Wald et al. that the affected
parent is the one with the higher LDL-C, which was estimated to
give a parental FPR of 4%, the PPV for parental screening would
be 60% (Fig. 3A). However, if the DR was actually 83% and the FPR
was 0.8%, as seen in the ALSPAC sequenced subsample alone, FPs
would greatly outnumber TPs (80 FP children to 17 TPs) with a
consequent fall in PPV (Fig. 3B). On the other hand, if the
assumption holds that there are no additional FH-mutation car-
riers among those with LDL-C<1.84MoM, the DR would be pre-
served but the FPR would fall to 0.2% (Fig. 3C). If however, the
true screening performance of an LDL-C cut-point of 1.84MoM is
closer to that estimated after adjustment for veriﬁcation bias, i.e.
a DR of 62.5% with a FPR of 0.2%, we estimated the PPV of the
1.84MoM LDL-C threshold would fall to 40% in both children and
parents (Fig. 3D). Misclassiﬁcation of case status due to NGS
having a 90% rather 100% DR for FH mutation had little additional
consequence (Fig. 3E).
Under all scenarios, the addition of an NGS step for samples
from all children who screen positive on the basis of an LDL-C,
would eliminate the FPs, if the DR and FPR of NGS are close to
100% and 0%, respectively, and reduce the rate of misclassiﬁcation
among the parents, because parents of children with false-positive
biochemical screening would be eliminated from subsequent
evaluation. Table 3 summarises the number of FH children and
affected parents identiﬁed for every 10,000 children screened,
under the range of scenarios discussed, with and without the
interpolation of an NGS step. An illustration of the screening pro-
cess is shown in Supplementary Fig. 3.4. Discussion
We evaluated the performance of a previously proposed
biochemical screening strategy for FH [12] in a large general pop-
ulation sample of 5083 nine-year old UK children, usingcomprehensive NGS methods for diagnosis of FH. Based on a
sequenced subsample of 1512 children, an LDL-C threshold of 1.84
MoM (4.25 mmol/L) led to a DR of 83%, close to that previously
estimated, but at a higher FPR (0.8%; 95% CI: 0.4e1.4%) than the pre-
speciﬁed 0.1% [12].
We re-estimated the screening performance of the proposed
LDL-C threshold after extrapolation to the whole cohort for two
extreme scenarios. In the ﬁrst, the assumption was made that no
further individuals with FH mutations would be found among
those with LDL-C<1.84 MoM. In the other, it was assumed that a
total of three FH mutation carriers (rather than one) would be ex-
pected among those with an LDL-C<1.84 MoM, thereby accounting
for veriﬁcation bias. The ﬁrst assumption yielded a DR for childhood
screening of 83% with an FPR of 0.2%, much closer to that estimated
byWald and colleagues. The second led to a much lower DR (62.5%)
with a similar FPR (0.2%) to the historical data. Thus, depending on
the assumptions, the accuracy of childhood screening for FH esti-
mated from historic case-control data could underestimate the FPR
or overestimate the DR, both of which would affect the efﬁciency of
parental screening.
We next modelled the effect of including an NGS step in all
screen positive samples, followed by the exclusion of parents of
children where sequencing did not conﬁrm a mutation (false-pos-
itives). Because of the very high DR and low FPR of NGS this would
have the beneﬁt of effectively eliminating parents of false-positive
children from the screening programme. The performance of such a
programme would then depend on the number of affected in-
dividuals ascertained which, in turn, depends on the DR of
biochemical screening.
In the best case scenario, with a DR of around 85%, followed by
NGS to eliminate false-positive samples, we estimated that 16 or 17
children and a similar number of parents (32e34 in total) would be
detected from the 40 parents and children expected to be affected
for every 10,000 children and 20,000 parents screened, assuming a
prevalence of 1 in 500. If the DR from biochemical screening is
closer to 63%, then 13 children and 13 parents (a total of 26 out of 40
affected individuals) would be ascertained. Estimates based on the
TC were markedly lower than for LDL-C.
There are several possible reasons for the higher biochemical
M. Futema et al. / Atherosclerosis 260 (2017) 47e5552
Fig. 3. (continued).
M. Futema et al. / Atherosclerosis 260 (2017) 47e55 53FPR in ALSPAC than that previously estimated[12]. Estimates of the
accuracy of biochemical screening of FH were previously derived
from studies inwhich childrenwere 1e9 years of age.Wemeasured
LDL-C at an average age of 9.9 years. The overlap of LDL-C between
affected and unaffected at this age may be higher than at a younger
age, leading to a higher FPR. The higher FPR in ALSPAC may also
simply reﬂect the play of chance, because of the small absolute
number of FH cases observed in a general population sample of this
size (six FH cases in a subsample of 1512 children, compared to 253
FH cases in the pooled analysis reported previously[12]). Changes
in diet and lifestyle may also have led to LDL-C in children being
different than in the period over which prior case-control studies
were reported. Controls in the historical data had higher median
LDL-C than the ALSPAC cohort (p < 1  104). This environmental
inﬂuence could affect the screening performance if it differentially
inﬂuenced LDL-C in children who carry a high burden of common,
small-effect LDL-C-raising alleles. We noted in the ALSPAC sample
(n ¼ 5083) that the average number of common LDL-C-raising al-
leles increased by the LDL-C quartile, but we did not have the power
in our sample to investigate a gene-environment interaction.
Alternatively, it may be that the published FPR estimate is lower
than could be achieved by a childhood screening programme. In
that analysis, cases were identiﬁed from lipid clinics, while controls
were unaffected siblings, or healthy individuals from general pop-
ulation surveys, and this might have accentuated differences in
LDL-C between cases and controls. Siblings of FH children might
have been exposed to healthier diets and lifestyles as a response to
having an FH diagnosis in the same family, while participants in
population surveys may have been healthier on average than those
who decline participation. The lower DR and higher FPR observed
in ALSPAC than when compared to the original report is also
consistent with the ﬁndings from the recent 10,000 child screening
project[14].
If FPR estimates are higher than previously estimated, this
would adversely affect the accuracy of biochemical screening of
children and their parents, as illustrated in Fig. 3. However, theFig. 3. Estimated performance of child-parent FH screening.
Estimated performance of child-parent FH screening in a hypothetical sample of 10,000 child
performance of LDL-C (1.84 MoM) compared with the historical data [12]; (B) DR and FPR in
mutations would be found; (D) extrapolation accounting for veriﬁcation bias; (E) extrapol
FPR ¼ false positive rate, PPV ¼ positive predictive value, OAPR ¼ odds of being affected ghigher than estimated FPR of biochemical screening in childhood
could be restored by NGS analysis of all biochemical screen positive
samples (Table 3). The accuracy, cost-effectiveness and accept-
ability of such an approach, as well as the performance of alter-
native sequencing approaches (whole genome, whole exome or
targeted sequencing), different sequencing technologies and bio-
infomatic pipelines for sequence interpretation, would require
separate study. Moreover, some individuals with an FH-causing
mutation may not present with LDL-C levels over the speciﬁed
cut-off because they have also inherited one or more common LDL-
C-lowering variants, for example the p. Arg46Leu loss-of-function
variant in PCSK9, thus inclusion of such known variants in the
sequencing step should be considered.
To fully assess the performance of child-parent screening,
samples from all mothers and fathers would have been available
but, unfortunately, this was not the case.Wewould also like to have
been able to sequence all samples from the ALSPAC study but this
was precluded by the currently high cost of sequencing. We
exploited the availability of information from low-read depth
sequencing from 1503 samples included in the UK10K project, but
were only able to conduct targeted NGS in a stratiﬁed random
subsample drawn from all four quartiles of the LDL-C distribution,
boosted by sequencing all samples from children with an LDL-
C>1.84MoM. This design introduced the potential for veriﬁcation
bias, which we accounted for as described above. Some further
technical limitations to our study are discussed in the
Supplementary Material section.
In conclusion, an LDL-C cut-point of 1.84MoM for the
biochemical screening in childhood could be inaccurate unless
performed soon either because of underestimation of the FPR or
overestimation of the DR. The performance of biochemical
screening for FH in childhood might be improved by assessment at
an age younger than 9 years, and/or by incorporating a sequential
NGS step to exclude false positives, and eliminate wasted screening
in the parental generation.ren and their parents, assuming a prevalence of FH 1 in 500, based on: (A) the observed
the sequenced sample; (C) extrapolation to the whole ALSPAC, assuming that no further
ation corrected for veriﬁcation bias and NGS sensitivity of 90%. (DR ¼ detection rate,
iven a positive result).
Table 3
Comparison of the number of correctly identiﬁed and misclassiﬁed FH individuals in a hypothetical sample of 10,000 children, between the historical data(13) and the current
study.
Predicted cases based on the
frequency of 1 in 500
Historical data ALSPAC data
Sequenced
data only
Extrapolated (if no further
mutations found)
Extrapolated
(adjusted
for veriﬁcation
bias)
Extrapolated (adjusted for
veriﬁcation bias and NGS
misclassiﬁcation)
DR ¼ 85%
FPR ¼ 0.1%
DR ¼ 83%
FPR ¼ 0.8%
DR ¼ 83%
FPR ¼ 0.2%
DR ¼ 63%
FPR ¼ 0.2%
DR ¼ 66.7%
FPR ¼ 0.2%
ID: M/C ID: M/C ID: M/C ID: M/C ID: M/C
Children
(N ¼ 10,000)
20 17: 10 17: 80 17: 20 13: 20 13: 20
Parents
(N ¼ 20,000)
20 16: 11 16: 81 16: 21 13: 20 13: 20
If initial biochemical screening was followed by NGS
Children
(N ¼ 10,000)
20 17: 0 17: 0 17: 0 13: 0 13: 0
Parents
(N ¼ 20,000)
20 17: 0 17: 0 17: 0 13: 0 13: 0
Under all scenarios, the interpolation of a NGS for samples from all children who screen positive on the basis of an LDL-C above the diagnostic threshold, would reduce the
misclassiﬁcation rate to 0%.
DR ¼ detection rate; FPR ¼ false positive rate; NGS ¼ next generation sequencing; ID: M/C ¼ ratio of identiﬁed to misclassiﬁed.
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